Regulation of human and mouse bystander T cell activation responses by PD-1.


Journal

JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073

Informations de publication

Date de publication:
22 09 2023
Historique:
received: 21 06 2023
accepted: 15 08 2023
medline: 25 9 2023
pubmed: 22 9 2023
entrez: 22 9 2023
Statut: epublish

Résumé

Bystander activation of memory T cells occurs via cytokine signaling alone in the absence of T cell receptor (TCR) signaling and provides a means of amplifying T cell effector responses in an antigen-nonspecific manner. While the role of Programmed Cell Death Protein 1 (PD-1) on antigen-specific T cell responses is extensively characterized, its role in bystander T cell responses is less clear. We examined the role of the PD-1 pathway during human and mouse non-antigen-specific memory T cell bystander activation and observed that PD-1+ T cells demonstrated less activation and proliferation than activated PD-1- populations in vitro. Higher activation and proliferative responses were also observed in the PD-1- memory population in both mice and patients with cancer receiving high-dose IL-2, mirroring the in vitro phenotypes. This inhibitory effect of PD-1 could be reversed by PD-1 blockade in vivo or observed using memory T cells from PD-1-/- mice. Interestingly, increased activation through abrogation of PD-1 signaling in bystander-activated T cells also resulted in increased apoptosis due to activation-induced cell death (AICD) and eventual T cell loss in vivo. These results demonstrate that the PD-1/PD-Ligand 1 (PD-L1) pathway inhibited bystander-activated memory T cell responses but also protected cells from AICD.

Identifiants

pubmed: 37737264
pii: 173287
doi: 10.1172/jci.insight.173287
pmc: PMC10561715
doi:
pii:

Substances chimiques

Programmed Cell Death 1 Receptor 0
Cytokines 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : P01 AI056299
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA214048
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL140921
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA093373
Pays : United States

Références

Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
J Exp Med. 2003 Jul 7;198(1):71-8
pubmed: 12847138
Aging Cell. 2016 Apr;15(2):291-300
pubmed: 26750587
J Virol. 2007 Nov;81(21):11749-57
pubmed: 17804505
Immunity. 2015 Aug 18;43(2):240-50
pubmed: 26231116
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Clin Exp Immunol. 2014 Jan;175(1):79-91
pubmed: 23937663
J Clin Oncol. 2020 May 20;38(15):1655-1663
pubmed: 32053428
J Virol. 2001 Jul;75(13):5965-76
pubmed: 11390598
J Virol Methods. 2006 Feb;131(2):122-9
pubmed: 16140399
Nat Rev Immunol. 2018 Mar;18(3):153-167
pubmed: 28990585
Blood. 2021 Sep 2;138(9):806-810
pubmed: 34473230
Nature. 2018 May;557(7706):575-579
pubmed: 29769722
Immunity. 1999 Dec;11(6):733-42
pubmed: 10626895
Nature. 2006 Feb 9;439(7077):682-7
pubmed: 16382236
J Immunol. 2018 Jan 15;200(2):375-383
pubmed: 29311378
Int Immunol. 1998 Oct;10(10):1563-72
pubmed: 9796923
J Immunol. 2014 Mar 15;192(6):2689-98
pubmed: 24510963
Nat Med. 2007 Mar;13(3):354-60
pubmed: 17334371
Science. 1996 Jun 28;272(5270):1947-50
pubmed: 8658169
Immunity. 2012 Sep 21;37(3):549-62
pubmed: 22940097
J Clin Invest. 2013 Jun;123(6):2604-15
pubmed: 23676462
J Infect Dis. 1993 Sep;168(3):725-9
pubmed: 8394863
Trends Immunol. 2018 Dec;39(12):1021-1035
pubmed: 30413351
J Exp Med. 2015 Jun 29;212(7):1125-37
pubmed: 26034050
Immunity. 2018 Jan 16;48(1):161-173.e5
pubmed: 29305140
Nat Rev Immunol. 2014 Jan;14(1):24-35
pubmed: 24336101
Exp Mol Med. 2020 Aug;52(8):1255-1263
pubmed: 32859954
Nat Rev Immunol. 2009 Jul;9(7):514-9
pubmed: 19543226
Cell Rep. 2020 Jun 30;31(13):107827
pubmed: 32610128
Blood. 2012 Mar 29;119(13):3073-83
pubmed: 22251483
J Virol. 2000 Apr;74(8):3650-8
pubmed: 10729141
J Clin Invest. 2001 Jul;108(1):51-62
pubmed: 11435457
Cytokine Growth Factor Rev. 2017 Aug;36:99-105
pubmed: 28629761
Crit Rev Immunol. 2016;36(1):57-74
pubmed: 27480902
Nat Rev Immunol. 2015 Aug;15(8):486-99
pubmed: 26205583
J Immunol. 2021 Feb 1;206(3):455-462
pubmed: 33468558
Sci Transl Med. 2012 Jun 6;4(137):137ra74
pubmed: 22674552
Immunol Today. 1990 Apr;11(4):113-5
pubmed: 2187466
J Immunother Cancer. 2020 May;8(1):
pubmed: 32467299

Auteurs

Catherine T Le (CT)

Department of Dermatology, School of Medicine, and.

Logan V Vick (LV)

Department of Dermatology, School of Medicine, and.

Craig Collins (C)

Department of Dermatology, School of Medicine, and.

Cordelia Dunai (C)

Department of Dermatology, School of Medicine, and.

Michael K Sheng (MK)

Department of Dermatology, School of Medicine, and.

Lam T Khuat (LT)

Department of Dermatology, School of Medicine, and.

Isabel Barao (I)

Department of Dermatology, School of Medicine, and.

Sean J Judge (SJ)

Department of Surgery, University of California, Davis, Sacramento, California, USA.

Ethan G Aguilar (EG)

Masonic Cancer Center, and Division of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA.

Brendan Curti (B)

Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Portland, Oregon, USA.

Maneesh Dave (M)

Department of Internal Medicine, Division of Gastroenterology, School of Medicine, University of California, Davis, Sacramento, California, USA.

Dan L Longo (DL)

Department of Medicine, Division of Hematology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Bruce R Blazar (BR)

Masonic Cancer Center, and Division of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA.

Robert J Canter (RJ)

Department of Surgery, University of California, Davis, Sacramento, California, USA.

Arta M Monjazeb (AM)

Department of Radiation-Oncology and.

William J Murphy (WJ)

Department of Dermatology, School of Medicine, and.
Department of Internal Medicine, Division of Hematology and Oncology, University of California, Davis School of Medicine, Sacramento, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH